Pfizer’s BLA for MenABCWY is Accepted by the US FDA as Preventive Measure for Meningococcal Disease
- PDUFA goal date set to access the BLA submission by Pfizer for its pentavalent meningococcal vaccine (covering 5 common serogroups, MenABCWY), is Oct 2023
- This BLA is based on the results from the P-III trial evaluating the safety, tolerability & immunogenicity of MenABCWY vs Trumenba + Menveo in adolescent patients (aged 10-25yr, n=2,400) across the US & Europe
- The MenABCWY is a combination of Pfizer’s licensed meningococcal vaccines, Trumenba & Nimenrix that is developed to protect against the meningococcal serogroups that is a lead cause in IMD
Ref: Businesswire | Image: Pfizer
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.